Related Experiment Video
Updated: Feb 23, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma
1Department of Ophthalmology, University of Cologne, Cologne, Germany.
Aim:
In this review, we outline similarities between conjunctival and skin melanoma as well as the effectiveness of combined BRAF/MEK inhibition in melanoma, and discuss the applicability of these agents in conjunctival melanoma.
Methods:
The study provides a PubMed literature review.
Results:
Conjunctival melanoma and skin melanoma are genetically and phenotypically related. Both tumors typically harbor BRAF mutations in more than 50% of cases. New targeted therapies in metastatic skin melanoma include selective inhibition of BRAF and MEK. Combined BRAF/MEK inhibition has revolutionized the treatment of metastatic skin melanoma, significantly improving patients' prognoses. While these new substances have been investigated extensively in the treatment of skin melanoma, comparable studies in conjunctival melanoma do not exist owing to the rarity of the malignancy.
Conclusions:
The application of combined BRAF/MEK inhibition in metastatic or unresectable conjunctival melanoma shows great potential for improving patients' prognoses. Future studies are needed to investigate the assumed benefit.
Insights
Combined BRAF/MEK inhibition shows promise for treating conjunctival melanoma, similar to its success in skin melanoma. Further research is needed to confirm its effectiveness for this rare cancer.
Area of Science:
- Oncology
- Dermatology
- Ophthalmology
Background:
- Conjunctival melanoma and skin melanoma share genetic and phenotypic similarities.
- BRAF mutations are prevalent in over 50% of both melanoma types.
- Targeted therapies, including BRAF/MEK inhibitors, have transformed metastatic skin melanoma treatment.
Purpose of the Study:
- To review similarities between conjunctival and skin melanoma.
- To assess the effectiveness of combined BRAF/MEK inhibition in melanoma.
- To discuss the potential application of these inhibitors in conjunctival melanoma.
Main Methods:
- A PubMed literature review was conducted.
- The review focused on genetic similarities and treatment responses.
- Existing data on BRAF/MEK inhibition in skin melanoma was analyzed.
Main Results:
- Conjunctival and skin melanomas are closely related genetically and phenotypically.
- BRAF mutations are common in both, exceeding 50% of cases.
- Combined BRAF/MEK inhibition significantly improves outcomes in metastatic skin melanoma, but studies in conjunctival melanoma are lacking due to rarity.
Conclusions:
- Combined BRAF/MEK inhibition holds significant potential for improving prognoses in metastatic or unresectable conjunctival melanoma.
- Further clinical studies are necessary to validate the efficacy of these targeted therapies in conjunctival melanoma.
More Related Videos
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...